e-Therapeutics is a pioneer in the field of network-driven drug discovery, NDD, using big data advanced network analytics and machine learning to identify compounds capable of significantly disrupting disease relevant biological networks. Just as big pharma is looking at in silico solutions to address the ongoing R&D productivity issues, e-Therapeutics is demonstrating the utility of its platform in areas of current interest. This fuels our confidence that the company will sign one or more drug discovery alliances in the coming year. To be conservative, our DCF valuation is unchanged at £53.8m or 20.4p/share.

Read our note at trinitydelta.org/e-therapeutics

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here